Synthetic Neuraminidase Vaccine Induces Cross-Species and Multi-Subtype Protection

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Influenza A virus genetic diversity challenges vaccine effectiveness.
• Current vaccines targeting hemagglutinin offer strain-specific immunity, often failing against divergent strains.

Purpose of the Study:

• To develop and evaluate a novel centralized consensus neuraminidase (NA) type 1 (N1CC) vaccine.
• To assess the immunogenicity and protective efficacy of the N1CC vaccine against diverse influenza strains.

Main Methods:

• Developed an N1CC vaccine using ancestral N1 sequences delivered via a human adenovirus type 5 vector.
• Evaluated antibody and T-cell responses in mice.
• Assessed vaccine efficacy in lethal influenza challenge models with human, swine, and avian H1N1 and H5N1 strains.

Main Results:

• The N1CC vaccine induced NA-specific antibody responses with inhibition activity and T-cell responses.
• N1CC vaccination provided complete protection against mortality in mice challenged with diverse H1N1 and H5N1 influenza strains.
• Demonstrated broad protection against human, swine, and avian influenza virus strains.

Conclusions:

• Neuraminidase (NA) is a viable target for a protective influenza vaccine.
• The centralized consensus NA vaccine design is effective and demonstrates broad protective potential.
• This approach offers a promising strategy to overcome influenza vaccine variability due to viral genetic diversity.